UnknownPhase 2/3

Profiling Antibody Status and Vaccine Effectiveness in Post Vaccination With SARS CoV2 in Ain Shams University

Egypt4,000 participantsStarted 2021-02-23

Plain-language summary

This is a prospective intervention study to assess the effectiveness of both the live attenuated and messenger RNA vaccines against SARS-CoV-2 infection

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age \> 18 years old
✓. Candidate for receiving vaccination according to health care authorties prioritaizaton

Exclusion criteria

✕. SARS-CoV-2 recovered cases \<3 months
✕. Individuals who are currently infected with Sars-COV-2 and/or with respiratory symptoms with fever.

What they're measuring

Short-term effectiveness

Timeframe: 21 days of the first dose of vaccine

Trial details

NCT IDNCT04885764

SponsorAin Shams University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-10-01

Contact for this trial

Samia Girgis, MD

01223366500 drsamia.girgis@med.asu.edu.eg

View on ClinicalTrials.gov More Covid19 trials